Does moxifloxacin alter oxidant status in the cornea? An experimental study

References

• Kernt M, Neubauer AS, Liegl RG, et al. Intracameral moxifloxacin: in vitro safety on human ocular cells. Cornea 2009;28:553–561
   PubMed Web of Science ®Google Scholar
• Miller JJ, Scott IU, Flynn HW Jr, et al. Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139:983–987
   PubMed Web of Science ®Google Scholar
• Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007;33:978–988
   Google Scholar
• Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol 2005;123:613–620
   PubMed Web of Science ®Google Scholar
• Ekinci Koktekir B, Aslan BS. Safety of prophylactic intracameral moxifloxacin use in cataract surgery. J Ocul Pharmacol Ther 2012;28:278–282
   PubMed Web of Science ®Google Scholar
• O'Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 2007;33:1790–1800
   PubMed Web of Science ®Google Scholar
• Kim SY, Park YH, Lee YC. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Exp Ophthalmol 2008;36:367–370
   PubMed Web of Science ®Google Scholar
• Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007;33:63–68
   PubMed Web of Science ®Google Scholar
• Kobayakawa S, Hiratsuka Y, Watabe Y, et al. Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model. Jpn J Ophthalmol 2010;54:481–485
   PubMed Web of Science ®Google Scholar
• Sato M, Oshika T. Survey of Japanese society of cataract and refractive surgery. IOL/RS (Jpn Soc IOL & Refract Surg) 2008;22:351–370
   Google Scholar
• Oshika T, Hatano H, Kuwayama Y, et al. Incidence of endophthalmitis after cataract surgery in Japan. Acta Ophthalmol Scand 2007;85:848–851
   PubMedGoogle Scholar
• Sosa AB, Epstein SP, Asbell PA. Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells. Cornea 2008;27:930–934
   PubMed Web of Science ®Google Scholar
• McDermott M, Wheater M. In vitro comparison of the effects of clinically available ophthalmic solutions of gatifloxacin 0.3% and moxifloxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expression. Cornea 2006;25:S25–S30
   Web of Science ®Google Scholar
• Tsai TH, Chen WL, Hu FR. Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells. Eye (Lond) 2010;24:909–917
   PubMed Web of Science ®Google Scholar
• Kim SY, Lim JA, Choi JS, et al. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 2007;26:720–725
   PubMed Web of Science ®Google Scholar
• Keating GM. Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis. Drugs 2011;71:89–99
   PubMed Web of Science ®Google Scholar
• Lockington D, Macdonald EC, Young D, et al. Presence of free radicals in intracameral agents commonly used during cataract surgery. Br J Ophthalmol 2010;94:1674–1677
   PubMed Web of Science ®Google Scholar
• Ulas T, Buyukhatipoglu H, Kirhan I, et al. The effect of day and night shifts on oxidative stress and anxiety symptoms of the nurses. Eur Rev Med Pharmacol Sci 2012;16:594–599
   PubMed Web of Science ®Google Scholar
• Ulas T, Buyukhatipoglu H, Kirhan I, et al. Evaluation of oxidative stress parameters and metabolic activities of nurses working day and night shifts. Rev Esc Enferm USP 2013;47:471–476
   PubMed Web of Science ®Google Scholar
• Yalcin S, Ulas T, Eren MA, et al. Relationship between oxidative stress parameters and cystatin C levels in patients with severe preeclampsia. Medicina (Kaunas) 2013;49:118–123
   PubMed Web of Science ®Google Scholar
• Ma JQ, Ding J, Zhang L, Liu CM. Hepatoprotective properties of sesamin against CCl4 induced oxidative stress-mediated apoptosis in mice via JNK pathway. Food Chem Toxicol 2014;64:41–48
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Komatsu T, Shigemi H, et al. BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine. BMC Cancer 2014;14:27
   PubMedGoogle Scholar
• Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103–1111
   PubMed Web of Science ®Google Scholar
• Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112–119
   PubMed Web of Science ®Google Scholar
• Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 2008;34:1451–1459
   PubMed Web of Science ®Google Scholar
• Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg 2008;34:1114–1120
   PubMed Web of Science ®Google Scholar
• Kernt M, Neubauer AS, Ulbig MW, et al. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg 2008;34:480–488
   PubMed Web of Science ®Google Scholar
• Price MO, Price FW Jr, Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J Cataract Refract Surg 2005;31:2137–2141
   PubMed Web of Science ®Google Scholar
• Donaldson KE, Marangon FB, Schatz L, et al. The effect of moxifloxacin on the normal human cornea. Curr Med Res Opin 2006;22:2073–2080
   PubMed Web of Science ®Google Scholar
• Matsuura K, Miyoshi T, Suto C, et al. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg 2013;39:1702–1706
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Ohashi Y, Matsumoto K, et al. Phase III comparative study of moxilloxacin ophthalmic solution in bacterial conjunctivitis (multi center, double masked study) (in Japanese). Atarashii Ganka 2007;24:1381–1394
   Google Scholar
• McGee DH, Holt WF, Kastner PR, Rice RL. Safety of moxifloxacin as shown in animal and in vitro studies. Surv Ophthalmol 2005;50:S46–S54
   PubMed Web of Science ®Google Scholar
• Gross RD, Lichtenstein SJ, Schlech BA, et al. Early clinical and microbiological responses in the treatment of bacterial conjunctivitis with moxifloxacin ophthalmic solution 0.5% (Vigamox™) using b.i.d. dosing. Today's Ther Trends 2003;21:227–237
   Google Scholar
• Granet DB, Dorfman M, Stroman D, Cockrum P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 2008;45:340–349
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Ohashi Y, Matsumoto K, et al. Phase III comparative study of moxilloxacin ophthalmic solution in bacterial conjunctivitis (multi center, double masked study) (in Japanese). Atarashii Ganka 2007;24:1381–1394
   Google Scholar
• Vigamox 5mg/ml eye drops, solution; EU summary of product characteristics. Hünenberg, Switzerland: Alcon; 2009
   Google Scholar
• Matsumoto S, Way W, Carlo K, Short B. Comparative toxicity of fluoroquinolones antibiotics on corneal cells in vitro. Cornea 2006;25:1–7
   Google Scholar
• Skelnik DL, Clark LA, Bezwada P. Effect of drug concentration and exposure time of levofloxacin, ofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin on human corneal endothelial cells and keratocytes (abstract). Invest Ophthalmol Vis Sci 2003;44:4739
   Google Scholar
• Walter K, Tyler ME. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases. Cornea 2006;25:855–857
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Perry HD, Chruscicki DA, et al. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. Curr Med Res Opin 2004;20:1753–1758
   PubMed Web of Science ®Google Scholar